Changes in functional status and inflammation profile in patients with chronic obstructive pulmonary disease during therapy with tiotropium
https://doi.org/10.21518/2079-701X-2015-16-8-13
Abstract
The article tells about the results of evaluating the effects of tiotropium on the level of bronchial hyperresponsiveness (BHR) and comparing its clinical efficacy in patients with chronic obstructive pulmonary disease (COPD) depending on the level of bronchial reactivity. Ttreatment with tiotropium was associated with a decrease in BHR (p <0.05) accompanied by a significant reduction in the severity of symptoms and frequency of COPD exacerbations, and improved quality of life compared to both baseline figures (p <0.05) and patients without BHR. COPD patients with BHR demonstrated higher efficacy of treatment with tiotropium compared with patients without BHR.
About the Authors
I. N. Trofimenko
Irkutsk State Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
B. A. Chernyak
Irkutsk State Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
References
1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org.
2. Barker BL, Brightling CE. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clin. Sci. (Lond), 2013, 124(6): 371-387.
3. Jones P, Miravitlles M, Van der Molen T et al. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int. J. Chron. Obstruct Pulmon. Dis., 2012, 7: 697709.
4. Burgel PR. From COPD definitions to COPD phenotypes. Presse Med., 2014, 43: 1337-1343.
5. Agusti А, Calverley PMA, Celli B et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort [Электронный ресурс]. Respir. Res., 2010, 11(1). Режим доступа: http//respira-tory-research.com/content/11/1/122.
6. Han MK, Muellerova H, Curran-Everett D et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med., 2013, 1: 43-50.
7. Baughman P, Marott JL, Lange P et al. Combined effect of lung function level and decline increases morbidity and mortality risks. Eur J. Epidemiol., 2012, 27(12): 933-943.
8. Drummond MB, Hansel NN, Connett JE et al. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med., 2012, 185(12): 1301-1306.
9. Han MK, Agusti A, Calverley PM et al. COPD phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med., 2010, 182: 598-604.
10. Burgel PR, Paillasseur JL, Caillaud D et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J., 2010, 36: 531-539.
11. Torok SS, Leuppi JD. Bronchial hyper-responsiveness and exhaled nitric oxide in chronic obstructive pulmonary disease. Swiss. Med. Wkly, 2007, 137: 385-391.
12. Yang SC, Lin BY. Comparison of Airway Hyperreactivity in Chronic Obstructive Pulmonary Disease and Asthma. Chang Gung Med.J., 2010, 33: 515-523.
13. Трофименко И.Н., Черняк БА. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология, 2011, 4: 49-53.
14. Fisher JT, Vincent SG, Gomeza J et al. Loss of vagally mediated bradycardia and bronchocon-striction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J., 2004, 18(6): 711-713.
15. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc.Am. Thorac. Soc., 2005, 2: 297-304.
16. Gulsvik A, RelVem OK. Ascoring system on respiratory symptoms. Eur. Respir.J., 1988, 1: 428-432.
17. Klein G, Kohler D, Bauer CP et al. Standartization of inhalation challenges for measuring the unspecific bronchial inhalation challenge by reservuar-method. Pneumologie, 1991, 45: 60-64.
18. Стандартизация легочных функциональных тестов. Пер. с англ. под ред. А.Г. Чучалина. М., 1993: 68-69.
19. Brutsche MH, Downs SH, Schindler C et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax., 2006, 61: 671-677.
20. De Marco R, Accordini S, Marcon A et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med., 2011, 183(7): 891-897.
21. Hospers JJ, Postma DS, Rijcken B et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet, 2000, 356: 1313-1317.
22. Трофименко И.Н., Батунова Е.В., Черняк Б.А. Взаимосвязь бронхиальной гиперреактивности и воспаления при хронической обструктивной болезни легких. Сиб. мед. журн. (г. Иркутск), 2012, 6: 51-54.
23. Buhling F, Lieder N, Kuhlmann UC, et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir. Med., 2007, 101(11): 2386-2394.
24. Kolahian S, Gosens R. Cholinergic Regulation of Airway Inflammation and Remodelling. J. Allergy (Cairo), 2012, 681258.
25. Cao R, Dong XW, Jiang JX et al. M (3) muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyper-responsiveness and remodeling in mice. Eur. J. Pharmacol, 2011, 655: 83-90.
Review
For citations:
Trofimenko IN, Chernyak BA. Changes in functional status and inflammation profile in patients with chronic obstructive pulmonary disease during therapy with tiotropium. Meditsinskiy sovet = Medical Council. 2015;(16):8-13. (In Russ.) https://doi.org/10.21518/2079-701X-2015-16-8-13
Views:
381
Email this article 